REZILIENT 4

Phase 3 Study of Zipalertinib plus adjuvant chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)..

Enquire

Trial overview

Clinical Area

Medical Oncology

Disease

Non-small cell lung cancer (NSCLC)

Disease site

Lung & bronchus

Study Phase

III

Trial Identifiers

Registration number: NCT07128199

https://clinicaltrials.gov/study/NCT07128199

GenesisCare Location(s)

St Leonards (North Shore Health Hub)

North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia

(02) 8037 4100

admin.northshore@genesiscare.com

Find out more Get directions

Principal Investigator(s)

Medical Oncologist

Prof. Nick Pavlakis

BSc MBBS MMed PhD FRACP

View Profile

Thank you for submitting.

We will be in touch within 24 hours

Form submission error

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

+61

Postalcode *

State/territory *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone Email

By clicking “submit” below, you acknowledge we will use the information you are providing to contact you about your referral request. Refer to our Private Policy for more information about how we handle personal information.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

Disclaimer: